Wecan Biotechnology

Wecan Biotechnology, also operating under the brand WestGene Biopharma, is a clinical-stage biotechnology company specializing in the development of mRNA-based vaccines and therapeutics. Headquartered in Chengdu, China, the company has built a comprehensive mRNA technology platform that encompasses sequence design, synthesis, and proprietary lipid nanoparticle (LNP) delivery systems. Its pipeline is led by a first-in-class EBV-related cancer mRNA vaccine (WGc-043) and a COVID-19 mRNA vaccine, alongside several programs targeting infectious diseases and solid tumors. Wecan Biotechnology distinguishes itself through its high-throughput screening capabilities and independent intellectual property in LNP delivery. The company aims to address significant unmet medical needs globally by leveraging the versatility and rapid development cycles of mRNA technology.